의료 규제 업무 아웃소싱 시장 분석 및 예측 : 기술별, 용도별, 최종 사용자별, 서비스 유형별, 제품 카테고리별, 개발 단계별, 서비스 제공 모델별, 도입 방식별(-2035년)

The global Healthcare Regulatory Affairs Outsourcing Market is projected to grow from $3.6 billion in 2025 to $10.2 billion by 2035, at a compound annual growth rate (CAGR) of 12.8%. In 2026, the Healthcare Regulatory Affairs Outsourcing market is expanding as pharmaceutical and biotechnology companies increasingly outsource regulatory submissions, clinical trial applications, and lifecycle management to handle rising compliance complexity and multi-region approval requirements across agencies such as the European Medicines Agency and the U.S. Food and Drug Administration; a clear stat-based instance of this demand is reflected in the EMAas 2023 regulatory workload, where the agency recommended 77 medicines for marketing authorization, including 39 containing a new active substance, each requiring extensive regulatory documentation review, scientific assessment, labeling validation, and post-approval compliance coordination processes that significantly increase reliance on outsourced regulatory writing, publishing, and submission management services to manage timelines and ensure accuracy across centralized approval procedures

Regulatory submissions & publishing services are driving the fastest growth in the Healthcare Regulatory Affairs Outsourcing Market due to the sharp increase in global drug approvals and the rising complexity of regulatory documentation requirements. Pharmaceutical and biotechnology companies are increasingly outsourcing dossier preparation, eCTD publishing, and lifecycle submissions to accelerate approvals and ensure compliance with evolving standards set by authorities such as the U.S. Food and Drug Administration. According to the U.S. Food and Drug Administration, the agency approved 50 novel drugs in 2024, reflecting sustained regulatory activity that directly increases demand for submission and publishing services. This growing volume of approvals, combined with multi-region filing requirements, continues to position this segment as the fastest expanding within regulatory outsourcing.

Regulatory consulting and strategy services continue to dominate the market by share, supported by their critical role across the entire product lifecycle, from early development to post-market compliance. Companies rely on outsourced regulatory expertise to navigate complex global frameworks, optimize approval pathways, and manage region-specific requirements, particularly as clinical trials and product launches expand internationally. Data from the European Medicines Agency shows that the EMA recommended 114 medicines for marketing authorization in 2024, highlighting the scale of regulatory activity and the need for continuous strategic guidance. This sustained regulatory workload reinforces consulting services as the largest revenue-generating segment within the healthcare regulatory affairs outsourcing market.

Geographical Overview

North America dominates the Healthcare Regulatory Affairs Outsourcing market due to its dense concentration of pharmaceutical and biotechnology firms, high regulatory scrutiny, and continuous drug approval activity under the U.S. Food and Drug Administration (FDA). In February 2026,regulatory workload intensity is the FDAas approval of multiple gene therapy and oncology treatments in recent years, including the approval expansion of CAR-T and rare disease therapies such as Zolgensma (onasemnogene abeparvovec), which required extensive regulatory submissions, risk evaluation, and post-marketing surveillance documentation processes frequently supported by outsourced regulatory writing and submission specialists to manage accelerated approval timelines.

Asia-Pacific is the significant growing region in the Healthcare Regulatory Affairs Outsourcing market, driven by rapid expansion in clinical development activity, increasing regulatory filings for biologics and biosimilars, and rising participation of China, India, Japan, and South Korea in global drug approval pathways. A recent real-world instance of this growth is the 2024 approval and regulatory progression of multiple innovative therapies in China under the National Medical Products Administration (NMPA), including accelerated approvals for oncology and rare-disease drugs such as Sotorasib (Lumakras) approval in China, which required complex bridging studies, multilingual regulatory dossiers, and simultaneous submissions across global agencies driving significant outsourcing of regulatory writing, submission publishing, and compliance coordination to manage parallel approval timelines efficiently.

Key Trends and Drivers

Rising Global Regulatory Workload and Expansion of Cross-Border Approvals:

The market is strongly driven by increasing regulatory complexity and growing multi-country approval requirements for pharmaceuticals and biologics, which is pushing companies to outsource regulatory writing, submissions, and lifecycle management. A real-world instance of this trend is the 2024 approval of multiple gene and cell therapy products under the U.S. FDAas accelerated pathways, including therapies such as Casgevy (exagamglogene autotemcel), which required extensive regulatory documentation, long-term safety monitoring frameworks, and coordinated global submission strategies across multiple jurisdictions driving increased dependence on outsourced regulatory affairs specialists to manage parallel regulatory processes efficiently.

Increasing Outsourcing Due to High-Volume Regulatory Submissions in Emerging Therapeutic Areas:

Another key driver is the rising number of complex submissions in advanced therapy areas such as gene therapy, rare diseases, and oncology, which require highly specialized regulatory expertise that many companies prefer to outsource. A clear real-world instance is the regulatory approval pathway for Lyfgenia (lovotibeglogene autotemcel) in 2023-2024, where extensive regulatory interactions, risk evaluation, and post-marketing commitments required continuous submission updates and multi-region documentation support leading sponsors to rely heavily on external regulatory consulting and publishing partners to manage submission complexity and ensure compliance across FDA and other global regulators.

Research Scope

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Service Type
• 2.2 Key Market Highlights by Product Category
• 2.3 Key Market Highlights by Stage
• 2.4 Key Market Highlights by Service Delivery Model
• 2.5 Key Market Highlights by Technology
• 2.6 Key Market Highlights by Application
• 2.7 Key Market Highlights by End User
• 2.8 Key Market Highlights by Deployment Mode

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Service Type (2020-2035)
  • 4.1.1 Regulatory Consulting
  • 4.1.2 Regulatory Strategy & Planning
  • 4.1.3 Regulatory Submissions & Publishing
  • 4.1.4 Clinical Trial Applications (CTA/IND/NDA/BLA)
  • 4.1.5 Product Registration & Market Authorization
  • 4.1.6 Regulatory Writing
  • 4.1.7 Lifecycle Management & Variations
  • 4.1.8 Pharmacovigilance & Post-Market Regulatory Services
  • 4.1.9 Others
• 4.2 Market Size & Forecast by Product Category (2020-2035)
  • 4.2.1 Pharmaceuticals
  • 4.2.2 Biologics
  • 4.2.3 Medical Devices
  • 4.2.4 Combination Products
  • 4.2.5 Nutraceuticals
  • 4.2.6 Cosmetics
  • 4.2.7 Others
• 4.3 Market Size & Forecast by Stage (2020-2035)
  • 4.3.1 Pre-Clinical
  • 4.3.2 Clinical
  • 4.3.3 Post-Marketing
  • 4.3.4 Lifecycle Management
• 4.4 Market Size & Forecast by Service Delivery Model (2020-2035)
  • 4.4.1 Full-Service Outsourcing
  • 4.4.2 Functional Service Provider (FSP)
  • 4.4.3 Project-Based Outsourcing
• 4.5 Market Size & Forecast by Technology (2020-2035)
  • 4.5.1 Regulatory Information Management Systems (RIMS)
  • 4.5.2 Electronic Document Management Systems (EDMS)
  • 4.5.3 eCTD Publishing Tools
  • 4.5.4 AI & Machine Learning
  • 4.5.5 Cloud-Based Platforms
  • 4.5.6 Data Analytics
  • 4.5.7 Others
• 4.6 Market Size & Forecast by Application (2020-2035)
  • 4.6.1 Regulatory Strategy Development
  • 4.6.2 Submission Management
  • 4.6.3 Compliance Management
  • 4.6.4 Labeling & Artwork Management
  • 4.6.5 Quality & Risk Management
  • 4.6.6 Others
• 4.7 Market Size & Forecast by End User (2020-2035)
  • 4.7.1 Pharmaceutical Companies
  • 4.7.2 Biotechnology Companies
  • 4.7.3 Medical Device Manufacturers
  • 4.7.4 Contract Research Organizations (CROs)
  • 4.7.5 Others
• 4.8 Market Size & Forecast by Deployment Mode (2020-2035)
  • 4.8.1 On-Premise
  • 4.8.2 Cloud-Based

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Service Type
    • 5.2.1.2 Product Category
    • 5.2.1.3 Technology
    • 5.2.1.4 Application
    • 5.2.1.5 Stage
    • 5.2.1.6 End User
    • 5.2.1.7 Service Delivery Model
    • 5.2.1.8 Deployment Mode
    • 5.2.1.9 Solutions
  • 5.2.2 Canada
    • 5.2.2.1 Service Type
    • 5.2.2.2 Product Category
    • 5.2.2.3 Technology
    • 5.2.2.4 Application
    • 5.2.2.5 Stage
    • 5.2.2.6 End User
    • 5.2.2.7 Service Delivery Model
    • 5.2.2.8 Deployment Mode
    • 5.2.2.9 Solutions
  • 5.2.3 Mexico
    • 5.2.3.1 Service Type
    • 5.2.3.2 Product Category
    • 5.2.3.3 Technology
    • 5.2.3.4 Application
    • 5.2.3.5 Stage
    • 5.2.3.6 End User
    • 5.2.3.7 Service Delivery Model
    • 5.2.3.8 Deployment Mode
    • 5.2.3.9 Solutions
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Service Type
    • 5.3.1.2 Product Category
    • 5.3.1.3 Technology
    • 5.3.1.4 Application
    • 5.3.1.5 Stage
    • 5.3.1.6 End User
    • 5.3.1.7 Service Delivery Model
    • 5.3.1.8 Deployment Mode
    • 5.3.1.9 Solutions
  • 5.3.2 Argentina
    • 5.3.2.1 Service Type
    • 5.3.2.2 Product Category
    • 5.3.2.3 Technology
    • 5.3.2.4 Application
    • 5.3.2.5 Stage
    • 5.3.2.6 End User
    • 5.3.2.7 Service Delivery Model
    • 5.3.2.8 Deployment Mode
    • 5.3.2.9 Solutions
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Service Type
    • 5.3.3.2 Product Category
    • 5.3.3.3 Technology
    • 5.3.3.4 Application
    • 5.3.3.5 Stage
    • 5.3.3.6 End User
    • 5.3.3.7 Service Delivery Model
    • 5.3.3.8 Deployment Mode
    • 5.3.3.9 Solutions
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Service Type
    • 5.4.1.2 Product Category
    • 5.4.1.3 Technology
    • 5.4.1.4 Application
    • 5.4.1.5 Stage
    • 5.4.1.6 End User
    • 5.4.1.7 Service Delivery Model
    • 5.4.1.8 Deployment Mode
    • 5.4.1.9 Solutions
  • 5.4.2 India
    • 5.4.2.1 Service Type
    • 5.4.2.2 Product Category
    • 5.4.2.3 Technology
    • 5.4.2.4 Application
    • 5.4.2.5 Stage
    • 5.4.2.6 End User
    • 5.4.2.7 Service Delivery Model
    • 5.4.2.8 Deployment Mode
    • 5.4.2.9 Solutions
  • 5.4.3 South Korea
    • 5.4.3.1 Service Type
    • 5.4.3.2 Product Category
    • 5.4.3.3 Technology
    • 5.4.3.4 Application
    • 5.4.3.5 Stage
    • 5.4.3.6 End User
    • 5.4.3.7 Service Delivery Model
    • 5.4.3.8 Deployment Mode
    • 5.4.3.9 Solutions
  • 5.4.4 Japan
    • 5.4.4.1 Service Type
    • 5.4.4.2 Product Category
    • 5.4.4.3 Technology
    • 5.4.4.4 Application
    • 5.4.4.5 Stage
    • 5.4.4.6 End User
    • 5.4.4.7 Service Delivery Model
    • 5.4.4.8 Deployment Mode
    • 5.4.4.9 Solutions
  • 5.4.5 Australia
    • 5.4.5.1 Service Type
    • 5.4.5.2 Product Category
    • 5.4.5.3 Technology
    • 5.4.5.4 Application
    • 5.4.5.5 Stage
    • 5.4.5.6 End User
    • 5.4.5.7 Service Delivery Model
    • 5.4.5.8 Deployment Mode
    • 5.4.5.9 Solutions
  • 5.4.6 Taiwan
    • 5.4.6.1 Service Type
    • 5.4.6.2 Product Category
    • 5.4.6.3 Technology
    • 5.4.6.4 Application
    • 5.4.6.5 Stage
    • 5.4.6.6 End User
    • 5.4.6.7 Service Delivery Model
    • 5.4.6.8 Deployment Mode
    • 5.4.6.9 Solutions
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Service Type
    • 5.4.7.2 Product Category
    • 5.4.7.3 Technology
    • 5.4.7.4 Application
    • 5.4.7.5 Stage
    • 5.4.7.6 End User
    • 5.4.7.7 Service Delivery Model
    • 5.4.7.8 Deployment Mode
    • 5.4.7.9 Solutions
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Service Type
    • 5.5.1.2 Product Category
    • 5.5.1.3 Technology
    • 5.5.1.4 Application
    • 5.5.1.5 Stage
    • 5.5.1.6 End User
    • 5.5.1.7 Service Delivery Model
    • 5.5.1.8 Deployment Mode
    • 5.5.1.9 Solutions
  • 5.5.2 France
    • 5.5.2.1 Service Type
    • 5.5.2.2 Product Category
    • 5.5.2.3 Technology
    • 5.5.2.4 Application
    • 5.5.2.5 Stage
    • 5.5.2.6 End User
    • 5.5.2.7 Service Delivery Model
    • 5.5.2.8 Deployment Mode
    • 5.5.2.9 Solutions
  • 5.5.3 United Kingdom
    • 5.5.3.1 Service Type
    • 5.5.3.2 Product Category
    • 5.5.3.3 Technology
    • 5.5.3.4 Application
    • 5.5.3.5 Stage
    • 5.5.3.6 End User
    • 5.5.3.7 Service Delivery Model
    • 5.5.3.8 Deployment Mode
    • 5.5.3.9 Solutions
  • 5.5.4 Spain
    • 5.5.4.1 Service Type
    • 5.5.4.2 Product Category
    • 5.5.4.3 Technology
    • 5.5.4.4 Application
    • 5.5.4.5 Stage
    • 5.5.4.6 End User
    • 5.5.4.7 Service Delivery Model
    • 5.5.4.8 Deployment Mode
    • 5.5.4.9 Solutions
  • 5.5.5 Italy
    • 5.5.5.1 Service Type
    • 5.5.5.2 Product Category
    • 5.5.5.3 Technology
    • 5.5.5.4 Application
    • 5.5.5.5 Stage
    • 5.5.5.6 End User
    • 5.5.5.7 Service Delivery Model
    • 5.5.5.8 Deployment Mode
    • 5.5.5.9 Solutions
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Service Type
    • 5.5.6.2 Product Category
    • 5.5.6.3 Technology
    • 5.5.6.4 Application
    • 5.5.6.5 Stage
    • 5.5.6.6 End User
    • 5.5.6.7 Service Delivery Model
    • 5.5.6.8 Deployment Mode
    • 5.5.6.9 Solutions
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Service Type
    • 5.6.1.2 Product Category
    • 5.6.1.3 Technology
    • 5.6.1.4 Application
    • 5.6.1.5 Stage
    • 5.6.1.6 End User
    • 5.6.1.7 Service Delivery Model
    • 5.6.1.8 Deployment Mode
    • 5.6.1.9 Solutions
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Service Type
    • 5.6.2.2 Product Category
    • 5.6.2.3 Technology
    • 5.6.2.4 Application
    • 5.6.2.5 Stage
    • 5.6.2.6 End User
    • 5.6.2.7 Service Delivery Model
    • 5.6.2.8 Deployment Mode
    • 5.6.2.9 Solutions
  • 5.6.3 South Africa
    • 5.6.3.1 Service Type
    • 5.6.3.2 Product Category
    • 5.6.3.3 Technology
    • 5.6.3.4 Application
    • 5.6.3.5 Stage
    • 5.6.3.6 End User
    • 5.6.3.7 Service Delivery Model
    • 5.6.3.8 Deployment Mode
    • 5.6.3.9 Solutions
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Service Type
    • 5.6.4.2 Product Category
    • 5.6.4.3 Technology
    • 5.6.4.4 Application
    • 5.6.4.5 Stage
    • 5.6.4.6 End User
    • 5.6.4.7 Service Delivery Model
    • 5.6.4.8 Deployment Mode
    • 5.6.4.9 Solutions
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Service Type
    • 5.6.5.2 Product Category
    • 5.6.5.3 Technology
    • 5.6.5.4 Application
    • 5.6.5.5 Stage
    • 5.6.5.6 End User
    • 5.6.5.7 Service Delivery Model
    • 5.6.5.8 Deployment Mode
    • 5.6.5.9 Solutions

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 PAREXEL International Corporation
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 ICON plc
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Charles River Laboratories
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 IQVIA
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Labcorp Drug Development
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Thermo Fisher Scientific
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Medpace Holdings Inc.
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 WuXi AppTec
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Syneos Health
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Genpact
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 Accenture
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Ergomed
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 ProPharma Group
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Freyr Solutions
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Kinapse
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 PharmaLex
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 Deloitte
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 Cognizant
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 Tata Consultancy Services (TCS)
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 Certara
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us